Payment overview · 2025
General Payments
$412.80
21 reported records · 12 companies
Healthcare provider profile · identity verified
Kenneth Dean Archer, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH RICHLAND HILLS, TX · NPI 1083654123
Verified facts
What the public records show
CMS Open Payments records show Kenneth Dean Archer, MD received $412.80 in general payments during 2025 across 21 reported records.
Lundbeck LLC accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $137.85 | 33.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.85 | 10.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $39.79 | 9.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $39.44 | 9.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.19 | 8.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.65 | 4.8% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $19.61 | 4.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.88 | 4.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.34 | 4.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.39 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.33 | 3.7% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $10.48 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.80 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $156.93 | 8 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $39.79 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $10.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
200 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
289 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
144 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1264 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1058 | 172 |
| Furosemide | Furosemide | 950 | 169 |
| Sertraline Hcl | Sertraline Hcl | 883 | 134 |
| Eliquis | Apixaban | 882 | 97 |
| Gabapentin | Gabapentin | 823 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 810 | 152 |
| Potassium Chloride | Potassium Chloride | 742 | 144 |
| Lisinopril | Lisinopril | 676 | 109 |
| Donepezil Hcl | Donepezil Hcl | 577 | 94 |
| Metformin Hcl | Metformin Hcl | 513 | 90 |
| Losartan Potassium | Losartan Potassium | 510 | 91 |
| Divalproex Sodium | Divalproex Sodium | 481 | 69 |
| Trazodone Hcl | Trazodone Hcl | 456 | 84 |
| Memantine Hcl | Memantine Hcl | 432 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 422 | 71 |
| Carvedilol | Carvedilol | 413 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 409 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 407 | 85 |
| Buspirone Hcl | Buspirone Hcl | 394 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 385 | 58 |
| Omeprazole | Omeprazole | 366 | 71 |
| Mirtazapine | Mirtazapine | 351 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 298 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 295 | 56 |
| Jardiance | Empagliflozin | 289 | 29 |
| Levetiracetam | Levetiracetam | 259 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 252 | 40 |
| Simvastatin | Simvastatin | 243 | 45 |
| Spironolactone | Spironolactone | 233 | 42 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 223 | 78 |
| Latanoprost | Latanoprost | 201 | 26 |
| Tramadol Hcl | Tramadol Hcl | 201 | 57 |
| Farxiga | Dapagliflozin Propanediol | 200 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 181 | 89 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 179 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 178 | 37 |
| Finasteride | Finasteride | 175 | 28 |
| Risperidone | Risperidone | 154 | 24 |
| Tradjenta | Linagliptin | 153 | suppressed |
| Famotidine | Famotidine | 151 | 37 |
| Alendronate Sodium | Alendronate Sodium | 145 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 144 | 18 |
| Trulicity | Dulaglutide | 144 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 140 | 26 |
| Olanzapine | Olanzapine | 138 | 19 |
| Montelukast Sodium | Montelukast Sodium | 137 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 137 | 64 |
| Xarelto | Rivaroxaban | 133 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 35 |
| Clonazepam | Clonazepam | 123 | 22 |
| Lamotrigine | Lamotrigine | 123 | 15 |
| Allopurinol | Allopurinol | 118 | 29 |
| Oxcarbazepine | Oxcarbazepine | 115 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 113 | 66 |
| Albuterol Sulfate | Albuterol Sulfate | 111 | 27 |
| Methocarbamol | Methocarbamol | 111 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 22 |
| Entresto | Sacubitril/Valsartan | 108 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 38 |
| Aripiprazole | Aripiprazole | 104 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 103 | 38 |
| Januvia | Sitagliptin Phosphate | 100 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 38 |
| Prednisone | Prednisone | 87 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 14 |
| Nyamyc | Nystatin | 86 | 44 |
| Tresiba Flextouch U-100 | Insulin Degludec | 85 | suppressed |
| Ozempic | Semaglutide | 84 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 83 | 22 |
| Bumetanide | Bumetanide | 82 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 81 | 14 |
| Topiramate | Topiramate | 80 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 30 |
| Nifedipine Er | Nifedipine | 78 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 76 | suppressed |
| Enulose | Lactulose | 74 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 28 |
| Sucralfate | Sucralfate | 70 | 11 |
| Ketoconazole | Ketoconazole | 68 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 67 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 67 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 22 |
| Lithium Carbonate | Lithium Carbonate | 67 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 67 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 37 |
| Baclofen | Baclofen | 66 | 14 |
| Bupropion Xl | Bupropion Hcl | 66 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 11 |
| Metformin Hcl Er | Metformin Hcl | 64 | 20 |
| Myrbetriq | Mirabegron | 64 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Prazosin Hcl | Prazosin Hcl | 64 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 39 |
| Atenolol | Atenolol | 61 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 60 | 16 |
| Pregabalin | Pregabalin | 60 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 58 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 33 |
| Clozapine | Clozapine | 57 | suppressed |
| Glimepiride | Glimepiride | 57 | 13 |
| Ezetimibe | Ezetimibe | 55 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 54 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 11 |
| Bupropion Hcl | Bupropion Hcl | 52 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 52 | 20 |
| Rivastigmine | Rivastigmine | 52 | suppressed |
| Lacosamide | Lacosamide | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Meloxicam | Meloxicam | 49 | 17 |
| Rexulti | Brexpiprazole | 47 | suppressed |
| Scopolamine | Scopolamine | 47 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 46 | 19 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 45 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 19 |
| Sevelamer Carbonate | Sevelamer Carbonate | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 27 |
| Acyclovir | Acyclovir | 39 | suppressed |
| Cyclosporine | Cyclosporine | 39 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 26 |
| Multaq | Dronedarone Hcl | 37 | suppressed |
| Alogliptin | Alogliptin Benzoate | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 14 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Belsomra | Suvorexant | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 24 |
| Incruse Ellipta | Umeclidinium Bromide | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 11 |
| Budesonide | Budesonide | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 22 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 31 | suppressed |
| Nystop | Nystatin | 31 | 19 |
| Hydrocortisone | Hydrocortisone | 30 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Tivicay | Dolutegravir Sodium | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Zonisamide | Zonisamide | 28 | suppressed |
| Letrozole | Letrozole | 27 | suppressed |
| Levemir | Insulin Detemir | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Topiramate Er | Topiramate | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 17 |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 13 |
| Atrovent Hfa | Ipratropium Bromide | 24 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 24 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 16 |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | 17 |
| Budesonide Er | Budesonide | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | 14 |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Valproic Acid | Valproic Acid | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | 13 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Austedo Xr | Deutetrabenazine | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 14 |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.80 · 21 records | Lundbeck LLC | AFREZZA, AIRSUPRA, AUSTEDO XR, CAPLYTA, FREESTYLE LIBRE 3, Fibroscan, INCEPTIV, KISUNLA, QULIPTA, REXULTI, VRAYLAR, VYEPTI, YUPELRI | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error